A recent study suggests that individuals who discontinue blockbuster weight-loss injections like semaglutide or tirzepatide may regain reduced body mass far faster than those who end traditional lifestyle plans.
Published data in a major health publication demonstrates that while obese people often shed about a fifth of their total mass while on the medication, the weight comes back at an estimated rate of nearly a kilo each month upon discontinuation.
"People purchasing these drugs should be aware of the potential of rapid rebound weight gain when the medication is stopped," warns researcher Dr. Susan Jebb.
This pace of regain implies a reversion to starting weight in about one and a half years.
Comparing Approaches
The study, which looked at 37 of studies involving over 9,000 of patients, contrasted the effects of these new drugs with conventional dieting.
Researchers point out that people who lose weight through diet and exercise generally see a slower weight regain—around 0.1 kg a month—after stopping.
Explaining the Quick Rebound
Doctors propose the mechanism of the injections accounts for the accelerated regain.
GLP-1 drugs copy a body's own chemical called glucagon-like peptide-1, which helps regulate hunger.
"Long-term administration of GLP-1 concentrations several times higher than the body's typical production could lead to the body to generate a reduced amount of its endogenous GLP-1, and may also reduce responsiveness to its effects," said Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this GLP-1 'fix' results in hunger is unsuppressed, making binge eating far more likely."
An Ongoing Disease?
Health authorities advise the jabs for people with obesity-related health risks, accompanied by prescribed diet and exercise modifications.
A number of clinicians say that, given the likelihood of relapse, the therapy is often ongoing.
This opinion is supported by pharmaceutical companies, who note that the findings "emphasize the long-term character of obesity," akin to managing diseases like diabetes.
User Testimonies
Individuals who have stopped the jabs describe a sudden return of cravings.
"It was like something that goes on and you become extremely hungry," said an individual.
The struggle is compounded if patients have not established lasting dietary or behavioural modifications during therapy.
Significant Adoption
Survey data suggest that millions of adults in the UK have tried weight-loss jabs in the last 12 months, with demand being substantial.
- Adoption is higher among females than males.
- The middle-aged demographic shows the highest level of interest.
- Many access the drugs through private healthcare rather than the NHS.
In conclusion, researchers emphasize that while these medications are potent agents for weight loss, they are not a standalone fix and lasting health benefits relies on combined behavioural support.
